Gemtuzumab ozogamicin in acute myeloid leukemia: act 2, with perhaps more to come

Documenti analoghi

• Gemtuzumab ozogamicin in acute myeloid leukemia: act 2, with perhaps more to come
  di: Johann Hitzler, et al.
  Pubblicazione: (2019-01-01)
• Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study
  di: Roland B. Walter, et al.
  Pubblicazione: (2014-01-01)
• Safety of gemtuzumab ozogamicin with cytarabine, daunorubicin, and midostaurin induction in FLT3-mutated AML
  di: Jayanshu Jain, et al.
  Pubblicazione: (2026-02-01)
• Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia
  di: Hassan Awada, et al.
  Pubblicazione: (2023-09-01)
• Gemtuzumab Ozogamicin in the Treatment of Critical Patients with Refractory Acute Myeloid Leukemia (3 Case Reports)
  di: Daniil Vladislavovich Zaitsev, et al.
  Pubblicazione: (2020-01-01)